| Basics |
Kura Oncology, Inc.
Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
|
| IPO Date: |
September 16, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.04B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.38 | 2.81%
|
| Avg Daily Range (30 D): |
$0.32 | 3.05%
|
| Avg Daily Range (90 D): |
$0.26 | 2.96%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.53M |
| Avg Daily Volume (30 D): |
1.83M |
| Avg Daily Volume (90 D): |
1.67M |
| Trade Size |
| Avg Trade Size (Sh.): |
91 |
| Avg Trade Size (Sh.) (30 D): |
93 |
| Avg Trade Size (Sh.) (90 D): |
97 |
| Institutional Trades |
| Total Inst.Trades: |
2,949 |
| Avg Inst. Trade: |
$1.83M |
| Avg Inst. Trade (30 D): |
$1.56M |
| Avg Inst. Trade (90 D): |
$1.36M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.97M |
| Avg Closing Trade (30 D): |
$1.84M |
| Avg Closing Trade (90 D): |
$1.49M |
| Avg Closing Volume: |
131.7K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.85
|
$-.75
|
|
Diluted EPS
|
|
$-.85
|
$-.75
|
|
Revenue
|
$
|
$ 20.75M
|
$ 15.29M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -74.12M
|
$ -66.12M
|
|
Operating Income / Loss
|
$
|
$ -80M
|
$ -72.67M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 13.34M
|
$ 30.68M
|
|
PE Ratio
|
|
|
|
|
|
|
